Why Shares of ImmunityBio Were Up on Wednesday

Shares of (NASDAQ: IBRX) were up 10% at 11:40 a.m. ET on Wednesday. The clinical-stage biotech company focuses on cell therapies and immunotherapy platforms, including vaccines and therapies to treat infections and cancers. The stock is down than 35% so far this year.

The company posted two research papers on Wednesday that may have helped drive the stock up. In the first, it reported that the company has developed a self-amplifying RNA (saRNA) vaccine for COVID-19 that, unlike mRNA vaccines, is stable at room temperature. That's important because other COVID-19 cold-chain requirements have hampered vaccine distribution, particularly in less wealthy countries. The paper says the saRNA/NLC vaccine, in preclinical studies, was able to induce a strong immunity. The therapy is currently in phase 1 trials.

The other paper showed that in a phase 2 trial of a treatment for acute myeloid leukemia patients, transplanted natural killer cells showed a strong response.

Source Fool.com

ImmunityBio Inc. Aktie

Leichte Gewinne bei der ImmunityBio Inc. Aktie heute, ein Anstieg um 0,45 %.
Gleichstand bei ImmunityBio Inc.: Die Anzahl der Buy- und Sell-Einschätzungen ist gleich.
Das von der Community festgelegte Kursziel für ImmunityBio Inc. von 10 € würde den aktuellen Kurs von 4.02 € mehr als verdoppeln.

Like: 0

IBRX

Teilen

TheMotleyFool

Rechtlicher Hinweis

Kommentare

| Discover the groundbreaking benefits of Prime Peptides Semaglutide, a game-changer in healing and immunity enhancement. Unleash your body's potential with this advanced peptide, accelerating recovery and promoting overall vitality. Dive into the world of Prime Peptides and experience the difference Semaglutide can make in your life.